Verification evidence is still being completed.
PDF / print export
Cimeio Therapeutics AG
Basel, Switzerland
- Verified lead
- Thomas Fuchs
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Shielded-Cell and Immunotherapy Pairs, Hematologic Disorders, and Gene Editing
- Review cycle
- 24 April 2026
- Full address
- Switzerland Innovation Park Basel Area, Allschwil, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Cimeio Therapeutics press release quoting CEO Thomas Fuchs on the cell-therapy platform patent issuance.
- Editorial note
- Basel shielded-cell therapy biotech with named CEO, 46 million CHF Series A from Versant Ventures, and Switzerland Innovation Park Basel Area tenancy.
Shielded-Cell and Immunotherapy Pairs, Hematologic Disorders, and Gene Editing
Versant Ventures-backed portfolio, Key patent issuance, Public CEO disclosure
Basel shielded-cell therapy biotech with named CEO, 46 million CHF Series A from Versant Ventures, and Switzerland Innovation Park Basel Area tenancy.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Basel, Switzerland
Cimeio Therapeutics AG
Shielded-Cell and Immunotherapy Pairs, Hematologic Disorders, and Gene Editing · Preclinical cell-therapy development
Basel shielded-cell therapy biotech with named CEO, 46 million CHF Series A from Versant Ventures, and Switzerland Innovation Park Basel Area tenancy.
- Lead
- Thomas Fuchs (verified ↗)
- Address
- Switzerland Innovation Park Basel Area, Allschwil, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical cell-therapy development
- Capabilities
- Shielded-Cell Technology Platform · Paired Immunotherapy Development · Hematologic Disorder Programs
- Founded
- 2021
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Thomas Fuchs
Chief Executive Officer
Full addressSwitzerland Innovation Park Basel Area, Allschwil, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Switzerland Innovation Park Basel Area resident directory for Cimeio Therapeutics.
Open sourcePreclinical cell-therapy development
Basel, Switzerland. Shielded-Cell and Immunotherapy Pairs, Hematologic Disorders, and Gene Editing. Review completed on 24 Apr 2026.
Swissmedic, FDA, and EMA for clinical-stage oversight
Versant Ventures-backed portfolio, Key patent issuance, Public CEO disclosure
Shielded-Cell and Immunotherapy Pairs, Hematologic Disorders, and Gene Editing
Basel shielded-cell therapy biotech with named CEO, 46 million CHF Series A from Versant Ventures, and Switzerland Innovation Park Basel Area tenancy.
Editorial note
Cimeio Therapeutics is a Basel cell-therapy biotech with a named CEO, a proprietary shielded-cell platform, a 46 million CHF Series A financing, and Switzerland Innovation Park Basel Area tenancy.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Shielded-Cell Technology Platform
Paired Immunotherapy Development
Hematologic Disorder Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Cell-shielding platform
Gene editing workflow
Paired immunotherapy development
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Cimeio Therapeutics AG located?
- Cimeio Therapeutics AG operates from Switzerland Innovation Park Basel Area, Allschwil, Switzerland, Basel, Switzerland.
- Who runs Cimeio Therapeutics AG?
- Cimeio Therapeutics AG is led by Thomas Fuchs, Chief Executive Officer. Verified 24 Apr 2026.
- What does Cimeio Therapeutics AG do?
- Basel shielded-cell therapy biotech with named CEO, 46 million CHF Series A from Versant Ventures, and Switzerland Innovation Park Basel Area tenancy. Core capabilities: Shielded-Cell Technology Platform, Paired Immunotherapy Development, Hematologic Disorder Programs.
Editorial context
Related technical briefs
Briefs that name Basel as a covered market or city.